MARKET

LIFE

LIFE

aTyr Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.510
+0.180
+5.41%
Pre Market: 3.420 -0.09 -2.56% 07:08 11/24 EST
OPEN
3.350
PREV CLOSE
3.330
HIGH
3.650
LOW
3.340
VOLUME
250
TURNOVER
--
52 WEEK HIGH
7.62
52 WEEK LOW
2.130
MARKET CAP
35.54M
P/E (TTM)
-1.3240
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
aTyr Pharma Q3 EPS $(0.68) Beats $(0.74) Estimate, Sales $148.00K Beat $100.00K Estimate
aTyr Pharma (NASDAQ:LIFE) reported quarterly losses of $(0.68) per share which beat the analyst consensus estimate of $(0.74) by 8.11 percent. This is a 53.74 percent increase over losses of $(1.47) per share from the
Benzinga · 11/12 21:23
aTyr Pharma, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 12, 2020 / aTyr Pharma, Inc.
ACCESSWIRE · 11/12 20:15
aTyr Pharma Announces Discovery of New Receptor Targets for Two tRNA Synthetases from its Pipeline
Discovery advances the understanding of extracellular tRNA synthetase pathways.Findings may contribute to the development of new therapeutics to treat cancer and fibrosis.SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it has identified receptor targets for two tRNA synthetases from its pipeline. The receptor targets may have utility in the development of new therapeutics to treat cancer and fibrosis. The company expects to present findings from this research at a scientific conference in the future.Human tRNA synthetases play a role in extracellular responses in certain disease states, including cellular stress and tissue homeostasis. Identifying target receptors for an extracellular tRNA synthetase helps inform discovery and development activities by providing additional focus towards relevant disease pathways and potential therapeutic applications.“We are pleased to advance our knowledge of this newly discovered area of biology by identifying these receptor targets. This represents a key milestone in our drug discovery efforts,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “The process by which we identified these receptor targets presents a novel approach to extracellular tRNA synthetase drug discovery and development and further validates our biology platform as one that can generate new potential drug targets. We look forward to exploring the pathways of these receptor targets and how they relate to altered disease states, which may contribute to the development of new therapeutic approaches in the areas of oncology and fibrosis, including potential new protein and antibody therapies.”The discovery work was completed as part of a research collaboration with CSL Behring, a global biotherapeutics leader specializing in immunology, hematology and other rare and serious medical conditions.About aTyraTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include statements regarding potential further research and development activities related to, and potential utility of, the newly-identified receptor targets, the potential therapeutic benefits and applications of our current and future product candidates, timelines and plans with respect to certain development activities, and certain development goals. These forward-looking statements also reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects, as reflected in or suggested by these forward-looking statements, are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. Furthermore, actual results may differ materially from those described in these forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, uncertainty regarding the COVID-19 pandemic, risks associated with the discovery, development and regulation of our product candidates, the risk that we or our partners may cease or delay preclinical or clinical development activities for any of our existing or future product candidates for a variety of reasons (including difficulties or delays in patient enrollment in planned clinical trials), the possibility that existing collaborations could be terminated early, and the risk that we may not be able to raise the additional funding required for our business and product development plans, as well as those risks set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.Contact: Ashlee Dunston Director, Investor Relations and Corporate Communications adunston@atyrpharma.com
GlobeNewswire · 11/10 12:00
aTyr Pharma Announces Research Collaboration with Medical University of South Carolina
Collaboration with leading expert Dr. Robert Gemmill will support the company’s neuropilin-2 (NRP2) antibody program in oncology. SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it has entered into a research collaboration with the Medical University of South Carolina (MUSC). Dr. Robert M. Gemmill, Ph.D., the former Melvyn Berlinksy Chair of Cancer Research and Professor of Medicine Emeritus in the Division of Hematology/Oncology at MUSC, will serve as the principal investigator for the collaboration. Dr. Gemmill’s research focuses on the genetic alteration of genes during lung and kidney cancer development, including the role of Neuropilin-2 (NRP2). The collaboration aims to accelerate the development of therapeutic antibodies that selectively target specific NRP2 isoforms and validate their potential use in the treatment of lung cancer.Lung cancer is the most common cancer and the leading cause of cancer death among men and women worldwide. Despite currently available treatments, many tumors become metastatic or develop resistance to targeted therapies. The development of new therapeutic strategies, which can enhance the existing therapeutic approaches and reduce or overcome drug resistance, are greatly needed. Research shows that aggressive forms of lung cancer are associated with higher expression of NRP2, a cell surface co-receptor involved in tumor progression and drug resistance, and specifically the splice variant NRP2b. Higher expression of NRP2 is linked to worsened patient outcomes in many cancers.“We are pleased to strengthen our academic partnerships and evolve our understanding of the role of NRP2 in lung cancer by entering into this research collaboration with Dr. Gemmill, a noted expert in the field of NRP2 biology and its role in cancer,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “Dr. Gemmill’s long-standing work in lung cancer is particularly aligned with aTyr’s belief that our antibodies have the potential to be engineered to inhibit the high expression of NRP2 often seen in aggressive tumors, including lung cancers. Despite currently available treatments, these aggressive tumors remain an area of high unmet medical need. We look forward to collaborating on future findings in this area.”“We know that NRP2 plays a role in both metastatic spread and acquired drug resistance leading to worsened patient survival,” noted Dr. Gemmill. “We look forward to the day when these life-threatening processes may be able to be blocked using NRP2 antibodies.”Dr. Gemmill graduated magna cum laude with a B.A. in Biology and a minor in Chemistry from the University of Connecticut. He received a Ph.D. in Biochemistry from Cornell University. He completed post-doctoral training in Molecular Biology for one year at Cornell and in Molecular Genetics for a second year at Arizona State University. He previously served as the Director of Molecular Genetics at The Genetics Center of the Southwest Biomedical Research Institute in Scottsdale, AZ, and Director of the Colorado Cancer Center Cytogenetics Laboratory. He was an Institute Fellow at the Eleanor Roosevelt Institute for Cancer Research in Denver, CO, and served as Professor in the Department of Medicine at the University of Colorado Health Sciences Center before moving to the Medical University of South Carolina, where he is Professor of Medicine, Emeritus.About NRP2Neuropilin-2 (NRP2) is a cell surface receptor that plays a key role in lymphatic development and in regulating inflammatory responses. In many forms of cancer, high NRP2 expression is associated with worse outcomes. NRP2 can interact with multiple ligands and co-receptors through distinct domains to influence their functional roles, making it a potential drug target with multiple distinct therapeutic applications. NRP2 interacts with type 3 semaphorins and plexins to impact inflammation and with forms of vascular endothelial growth factor (VEGF) and their receptors, to impact lymphangiogenesis. In addition, NRP2 modulates interactions between CCL21 and CCR7 potentially impacting homing of dendritic cells to lymphoid organs. aTyr is currently investigating NRP2 receptor biology, both internally and in collaboration with key academic thought leaders, as a novel target for new product candidates for a variety of diseases, including cancer and inflammation.About aTyraTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include statements regarding the potential therapeutic benefits and applications of NRP2 antibodies; timelines and plans with respect to certain development activities, potential benefits of collaborations and certain development goals. These forward-looking statements also reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects, as reflected in or suggested by these forward-looking statements, are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. Furthermore, actual results may differ materially from those described in these forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, uncertainty regarding the COVID-19 pandemic, risks associated with the discovery, development and regulation of our product candidates, the risk that we or our partners may cease or delay preclinical or clinical development activities for any of our existing or future product candidates for a variety of reasons (including difficulties or delays in patient enrollment in planned clinical trials), the possibility that existing collaborations could be terminated early, and the risk that we may not be able to raise the additional funding required for our business and product development plans, as well as those risks set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Contact: Ashlee Dunston Investor Relations, aTyr Pharma adunston@atyrpharma.com
GlobeNewswire · 10/29 12:00
aTyr Pharma to Participate in ROTH Capital Partners Webinar on COVID-19 Therapeutics in Development on October 28th
SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will participate in a panel titled, “Immune Modulators to Ameliorate COVID-19” as part of the ROTH Capital Partners Webinar on COVID-19 Therapeutics in Development on October 28, 2020. Details of the event are as follows:Event: ROTH Capital Partners Webinar on COVID-19 Therapeutics in Development Panel: Immune Modulators to Ameliorate COVID-19 Date: Wednesday, October 28, 2020 Time: 9:00 a.m. – 10:20 a.m. Eastern TimeRegistration for the webinar is available on the Investor’s section of the Company’s website at www.atyrpharma.com. A replay of the live webcast will be available on the Company’s website following the event.About aTyraTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.Contact: Ashlee Dunston Investor Relations, aTyr Pharma adunston@atyrpharma.com
GlobeNewswire · 10/27 11:00
aTyr Pharma concludes enrollment in mid-stage ATYR1923 study in COVID-19 patients
ATyr Pharma (LIFE) has completed enrollment of 32 subjects in Phase 2 clinical trial of its lead therapeutic candidate, ATYR1923 in hospitalized COVID-19 patients with severe respiratory complications who do not require
Seekingalpha · 10/26 11:50
aTyr Pharma Announces Completion Of Enrollment In Phase 2 Clinical Trial Of ATYR1923 In COVID-19 Patients With Severe Respiratory Complications
Topline results are expected in the fourth quarter of 2020.   Trial evaluating the preliminary safety and efficacy of ATYR1923 vs placebo has exceeded enrollment. SAN DIEGO, Oct. 26,
Benzinga · 10/26 11:01
Oppenheimer sees divided sector in 'critical' months for biotech
Heading into earnings season for biotech stocks, Oppenheimer is expecting two kinds of companies to come out on the other side: growth or growth-potential names continuing to dominate in an
Seekingalpha · 10/08 23:22
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LIFE. Analyze the recent business situations of aTyr Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LIFE stock price target is 13.33 with a high estimate of 15.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 47
Institutional Holdings: 6.41M
% Owned: 63.28%
Shares Outstanding: 10.12M
TypeInstitutionsShares
Increased
10
214.36K
New
8
-10.86K
Decreased
2
40.84K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.80%
Pharmaceuticals & Medical Research
-0.36%
Key Executives
Chairman/Independent Director
John Clarke
President/Chief Executive Officer/Director
Sanjay Shukla
Chief Financial Officer
Jill Broadfoot
General Counsel/Secretary
Nancy Krueger
General Counsel/Secretary
Nancy Denyes
Independent Director
Timothy Coughlin
Independent Director
Jane Gross
Independent Director
Jeffrey Hatfield
Independent Director
Svetlana Lucas
Independent Director
Paul Schimmel
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About LIFE
aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of aTyr Pharma Inc stock information, including NASDAQ:LIFE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LIFE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LIFE stock methods without spending real money on the virtual paper trading platform.